COMMUNIQUÉS West-GlobeNewswire

CMR Surgical Submits 510(k) Application to U.S. FDA to Expand Versius Plus™ into Gynecology
29/04/2026
PRESS RELEASE Following Recent FDA Clearance for Cholecystectomy, the Company is now 510(k) pending for Gynecology. This Submission Builds On Extensive Global Clinical Experience in Gynecology and Continues CMR’s U.S. [...]
ORYZON to Participate in Upcoming Events in May and June
29/04/2026
Updated data from iadademstat’s clinical trials in acute myeloid leukemia to be presented at EHA-2026 in June MADRID and CAMBRIDGE, Mass., April 29, 2026 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: [...]
SkinHealth Systems to Report First Quarter 2026 Financial Results on May 7, 2026
29/04/2026
LONG BEACH, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- SkinHealth Systems Inc. (formerly The Beauty Health Company; Nasdaq: SKIN), a global medical aesthetics company, today announced it will report first quarter 2026 [...]
EnteroBiotix Secures £19m to Initiate Phase 2b Clinical Trial for Irritable Bowel Syndrome
29/04/2026
Funds will support one of the largest interventional clinical trials of a full-spectrum microbiome product, and the largest ever to be conducted in IBS Dosing of first patient of the Phase 2b ‘RISE’ trial anticipated in [...]
Sangamo Therapeutics Announces Transition to Trading on OTCQB Venture Market
29/04/2026
Sangamo’s common stock to transition trading from The Nasdaq Capital Market to OTCQB Venture Market beginning May 5, 2026 RICHMOND, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a [...]
UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026
29/04/2026
Conference Call and Webcast Scheduled for Wednesday, May 6th, 2026, at 10:00 AM ET PRINCETON, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and [...]
Ontario Building Code Review Points to a Clear Win for Families and Future Homeowners: Prevent Lung Cancer Cases by Keeping Radon Mitigation Measures in Place
29/04/2026
Lung Health Foundation says existing protections are simple, effective safeguards worth preserving TORONTO, April 29, 2026 (GLOBE NEWSWIRE) -- As Ontario moves to speed up housing construction by cutting red tape, Lung [...]
Ocugen to Host Conference Call on Tuesday, May 5 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2026 Financial Results
29/04/2026
MALVERN, Pa., April 29, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it will host a [...]
Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI
29/04/2026
SAN DIEGO, April 29, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, announced [...]
Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update
29/04/2026
NOVATO, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra [...]
Picard Medical / SynCardia Featured in Interview Series with The Mullings Group
29/04/2026
– Discussions to highlight total artificial heart therapy, advanced heart failure market, and next-generation platform development – TUCSON, Ariz., April 29, 2026 (GLOBE NEWSWIRE) -- Picard Medical, Inc. (NYSE American [...]
RenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ET
29/04/2026
MOUNTAIN VIEW, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies and commercializing [...]
Biomerica’s inFoods® IBS Data Accepted for Presentation at Digestive Disease Week 2026
29/04/2026
Real-world clinical experience with the novel IBS-specific guided diagnostic therapy to be presented at the world’s largest GI medical conference, May 2–5, 2026, in Chicago IRVINE, Calif., April 29, 2026 (GLOBE NEWSWIRE [...]
Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis
29/04/2026
Patient enrollment accelerates across expanding number of clinical trial sites in multiple countries 8 patients enrolled, with additional patients expected in the near term Enrollment initiated in March 2026, with [...]
GH Research Announces Pricing of $117.5 Million Underwritten Offering
29/04/2026
DUBLIN, April 29, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in [...]
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
29/04/2026
DALLAS, April 29, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene [...]
MindBio Files Patent Applications in 15 World Firsts
29/04/2026
Using Voice and AI to Detect Drug & Alcohol Intoxication 15 world first discoveries transform our understanding of physiological reactions to neurologically active substances that when consumed, affect the central [...]
electroCore to Announce First Quarter March 31, 2026, Financial Results on Wednesday, May 6, 2026
29/04/2026
ROCKAWAY, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the first [...]
Adial Pharmaceuticals Advances IP Portfolio with New U.S. Utility Patent Application, Positioning for Potential Market Exclusivity Through 2045
29/04/2026
New U.S. utility patent application targeting patient populations with demonstrated heightened responsiveness to ondansetron treatment, reinforcing Adial’s precision-medicine approach GLEN ALLEN, Va., April 29, 2026 ( [...]

Pages